Association between statin use and the risk of colorectal cancer in patients with inflammatory bowel disease: a systematic review and meta-analysis.
[BACKGROUND] Patients with inflammatory bowel disease (IBD) are at increased risk of colorectal cancer (CRC).
- p-value p = 0.03
- 95% CI 0.69-0.87
- RR 0.77
- 연구 설계 systematic review
APA
Ding M, Liu Y, et al. (2025). Association between statin use and the risk of colorectal cancer in patients with inflammatory bowel disease: a systematic review and meta-analysis.. Frontiers in immunology, 16, 1693342. https://doi.org/10.3389/fimmu.2025.1693342
MLA
Ding M, et al.. "Association between statin use and the risk of colorectal cancer in patients with inflammatory bowel disease: a systematic review and meta-analysis.." Frontiers in immunology, vol. 16, 2025, pp. 1693342.
PMID
41624878
Abstract
[BACKGROUND] Patients with inflammatory bowel disease (IBD) are at increased risk of colorectal cancer (CRC). Statins exhibit anti-inflammatory and anticancer properties, and although prior meta-analyses have suggested a possible reduction in CRC risk among patients with IBD, the evidence remains limited by small study numbers and methodological constraints.
[METHODS] We conducted a systematic review and meta-analysis of observational studies comparing CRC incidence between statin users and non-users in IBD populations. PubMed, Embase, and Web of Science databases were searched for relevant studies on May 22, 2025. Data were pooled using a random-effects model, and relative risks (RRs) with 95% confidence intervals (CIs) were calculated. Subgroup and meta-regression analyses were performed to explore potential effect modifiers.
[RESULTS] Nine datasets from seven studies involving 639,595 IBD patients were included. Statin use was associated with a significantly reduced CRC risk (RR = 0.77, 95% CI: 0.69-0.87; I² = 27%). The association remained robust in sensitivity analyses and was stronger in high-quality studies (RR = 0.65, 95% CI: 0.54-0.78; I² = 0%). Meta-regression identified follow-up duration as a significant modifier (p = 0.03), and subgroup analysis confirmed that studies with >5 years of follow-up reported a greater risk reduction (p for subgroup difference = 0.02). No significant publication bias was detected (Egger's test p = 0.35).
[CONCLUSIONS] Statin use is associated with a lower risk of CRC in patients with IBD, particularly in studies with longer follow-up. These findings support further research on the chemopreventive potential of statins in this high-risk population.
[SYSTEMATIC REVIEW REGISTRATION] https://www.crd.york.ac.uk/prospero/, identifier CRD420251038799.
[METHODS] We conducted a systematic review and meta-analysis of observational studies comparing CRC incidence between statin users and non-users in IBD populations. PubMed, Embase, and Web of Science databases were searched for relevant studies on May 22, 2025. Data were pooled using a random-effects model, and relative risks (RRs) with 95% confidence intervals (CIs) were calculated. Subgroup and meta-regression analyses were performed to explore potential effect modifiers.
[RESULTS] Nine datasets from seven studies involving 639,595 IBD patients were included. Statin use was associated with a significantly reduced CRC risk (RR = 0.77, 95% CI: 0.69-0.87; I² = 27%). The association remained robust in sensitivity analyses and was stronger in high-quality studies (RR = 0.65, 95% CI: 0.54-0.78; I² = 0%). Meta-regression identified follow-up duration as a significant modifier (p = 0.03), and subgroup analysis confirmed that studies with >5 years of follow-up reported a greater risk reduction (p for subgroup difference = 0.02). No significant publication bias was detected (Egger's test p = 0.35).
[CONCLUSIONS] Statin use is associated with a lower risk of CRC in patients with IBD, particularly in studies with longer follow-up. These findings support further research on the chemopreventive potential of statins in this high-risk population.
[SYSTEMATIC REVIEW REGISTRATION] https://www.crd.york.ac.uk/prospero/, identifier CRD420251038799.
MeSH Terms
Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Colorectal Neoplasms; Inflammatory Bowel Diseases; Risk Factors; Incidence; Risk Assessment
같은 제1저자의 인용 많은 논문 (5)
- Enhanced Remission and Survival Outcomes with Decitabine Plus Venetoclax in Additional Sex Comb Like 1 Mutated Acute Myeloid Leukemia.
- Resveratrol Inhibits Pancreatic Cancer Progression by Regulating CDC42 Succinylation and Disrupting the Extracellular Matrix.
- COL8A1-positive cancer-associated fibroblasts are drivers of 5-fluorouracil resistance in colorectal cancer.
- Catch and light up: Dual bioorthogonal reactions actualize fluorescent probe retention and activation for surgical navigation.
- Clinical Characteristics and Prognostic Factors Associated with Herpes Zoster in Patients with Malignant Tumors: A Systematic Review and Meta-analysis.